DCAKD Inhibitors
DCAKD, or Decapping Kinase DCAKD, plays a crucial role in mRNA decapping, a process essential for mRNA degradation and thus regulation of gene expression. As an enzyme involved in post-transcriptional regulation, DCAKD influences the stability and turnover of mRNAs, impacting cellular protein synthesis. The precise modulation of mRNA decapping is vital for maintaining cellular homeostasis and responding to various stress conditions. DCAKD's activity ensures that mRNAs are appropriately degraded after their functional lifetime, preventing the accumulation of unwanted or damaged mRNA transcripts which could lead to aberrant protein production.
Inhibition of DCAKD, therefore, represents a potential mechanism to alter gene expression profiles by affecting mRNA stability and degradation pathways. Indirect inhibitors of DCAKD, such as those affecting signaling pathways or enzymes that regulate DCAKD's activity or expression, might modulate its function by altering phosphorylation states, changing cofactor availability, or influencing the cellular localization of DCAKD. This could lead to a decreased decapping activity, resulting in the stabilization of specific mRNAs and thereby affecting protein synthesis. The general mechanism of inhibition could involve changes in cellular signaling cascades, modulation of other kinases or phosphatases that interact with DCAKD, or alterations in the cellular environment that impact DCAKD's activity. Understanding the complex interplay between DCAKD and its indirect inhibitors offers insights into how modulation of mRNA decapping can influence cellular processes and gene expression regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that broadly targets protein kinases, including those involved in the phosphorylation processes DCAKD may regulate. By inhibiting these kinases, staurosporine indirectly reduces DCAKD's substrate availability, leading to its functional suppression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can modulate AKT signaling, indirectly affecting pathways that DCAKD might influence. Through PI3K/AKT pathway inhibition, it could lead to alterations in cellular processes modulated by DCAKD, including mRNA decapping. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, components of the MAPK pathway, potentially influencing pathways upstream of DCAKD. By impeding MAPK signaling, U0126 may indirectly affect the regulatory mechanisms DCAKD is involved in, leading to its suppression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor that, by blocking the PI3K/AKT pathway, might indirectly affect DCAKD's role in cellular signaling. Its action could lead to a decrease in the processes DCAKD is purported to regulate. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAP kinase inhibitor that could impact signaling pathways indirectly involving DCAKD. By inhibiting p38, it may modulate cellular responses that DCAKD is part of, leading to its indirect suppression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific MEK inhibitor that by blocking the MAPK/ERK pathway might indirectly affect DCAKD's activity. This suppression of ERK signaling could lead to alterations in DCAKD-mediated processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that impacts cellular growth and metabolism pathways, potentially affecting those regulated by DCAKD. Through mTOR pathway inhibition, rapamycin might indirectly suppress DCAKD's functional aspects. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
A JNK inhibitor potentially impacting stress response pathways where DCAKD may play a role. By inhibiting JNK signaling, Sp600125 could indirectly reduce DCAKD's involvement in these pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor, potentially affecting signaling cascades involving DCAKD. By inhibiting Src kinases, PP2 could indirectly lead to suppression of DCAKD's activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor that might affect signaling pathways involving DCAKD. Its broad inhibition of tyrosine kinases could lead to indirect suppression of DCAKD. | ||||||